Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the first subject has been enrolled in a confirmatory clinical study for its aminolevulinic acid used in the intraoperative visualization of advanced gliomas. This development comes as the company seeks to enhance surgical outcomes for patients with this challenging form of brain cancer.
Aminolevulinic acid is designed to utilize fluorescence-guided technology to highlight the boundaries of gliomas, assisting surgeons in more accurately removing tumors while preserving healthy tissue. The study aims to evaluate the efficacy and safety of the drug in fluorescence-guided resection of malignant high-grade (WHO grade III-IV) gliomas.- Flcube.com
